Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The APP[V717I] London (APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer's disease (AD) and is therefore a valuable paradigm for evaluating therapeutic candidates. Historically, both the parenchymal and vascular amyloid deposits, and more recently, truncated and pyroglutamate-modified Abet species, are perceived as important hallmarks of AD-pathology. Late stage symptoms are preceded by robust deficits in orientation and memory that correlate in time with Abeta oligomerization and GSK3-mediated phosphorylation of endogenous murine Tau, all markers that have gained considerable interest during the last decade. Clinical parallels with AD patients and the value of the APP-Ld transgenic mouse model for preclinical in vivo testing of candidate drugs are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 2×
“…Transgenic Mouse Model An Tanghe,1 Annelies Termont,1 Pascal Merchiers,2 Stephan Schilling,3 Hans-Ulrich Demuth,3 Louise Scrocchi,4 Fred Van Leuven,5 Gerard Griffioen,1 and Tom Van Dooren1 1 reMYND NV, Gaston Geenslaan 1, 3001 Heverlee-Leuven, Belgium 2 Ablynx NV, Technologiepark 214, 9052…”
BackgroundInfluentialThe amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · cited 2×
“…Transgenic Mouse Model An Tanghe,1 Annelies Termont,1 Pascal Merchiers,2 Stephan Schilling,3 Hans-Ulrich Demuth,3 Louise Scrocchi,4 Fred Van Leuven,5 Gerard Griffioen,1 and Tom Van Dooren1 1 reMYND NV, Gaston Geenslaan 1, 3001 Heverlee-Leuven, Belgium 2 Ablynx NV, Technologiepark 214, 9052…”
BackgroundInfluentialEpilepsy and Cognitive Impairments in Alzheimer Disease
Palop, J. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.15 · Cited by 684 · cited 1×
“Premature death caused by epileptic seizures is an epiphenomenon observed in Alzheimer patients [32, 33] and is also found in the APPLd model [9].”
ResultMoechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 1×
“Thus, APP-Ld mice display a high relative concentration of Abeta42, the more fibrillogenic Abeta species, essential for amyloid deposition in the parenchyma and vessels [12].”
BackgroundSaido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · cited 1×
“These N-terminal truncated Abeta species are abundant in amyloid deposits in sporadic and familial AD [22].”
BackgroundGlutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology
Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., et al. (2008) · Nature Medicine · doi:10.1038/nm.1872 · Cited by 357
Self-citationTomic, J. L., Pensalfini, A., Head, E., & Glabe, C. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.024 · Cited by 336 · cited 3×
“The similarity with AD patients is striking, especially in light of recent findings demonstrating that soluble oligomers species were elevated in AD brain and appear to correlate with cognitive decline and neuropathological hallmarks [35].”
BackgroundInfluentialHeneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., & Van Leuven, F. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-22 · Cited by 309 · cited 2×
“Interestingly, neuronal BACE1 expression was demonstrated to be upregulated in close proximity of activated microglia and astrocytes, strongly pointing to an interaction between neurodegenerative and neuroinflammatory events [37].”
Neuropathologic Alterations in Mild Cognitive Impairment: A Review
Markesbery, W. R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1220 · Cited by 236 · cited 1×
“A similar dissociation of amyloid plaque pathology and behavioral aspects was observed in mild cognitive impairment (MCI) patients [34].”
BackgroundWirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.-U., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0557-5 · Cited by 174 · cited 1×
“They resist proteolysis, accelerate aggregation by seeding and thereby entrapping other Abeta forms, and are claimed to be neurotoxic [23].”
BackgroundSelf-citationAdditive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein
Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C., Ostaszewski, B. L., Xia, W., Levesque, G., St. George Hyslop, P., Younkin, S. G., & Selkoe, D. J. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0183 · Cited by 101 · cited 1×
“The aggravated Abeta pathobiology in the APP∗PS1 double transgenic mouse recapitulates the effect of the early-onset familial Alzheimer disease (EOFAD) PS1 mutations on the metabolism of APP [42].”
Background
Cited by
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427
Self-citationPerez-Cruz, C., Nolte, M. W., van Gaalen, M. M., Rustay, N. R., Termont, A., Tanghe, A., Kirchhoff, F., & Ebert, U. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6142-10.2011 · Cited by 172
“clinical and drug developmental studies (Hsiao et al., 1996; Moechars et al., 1999; Tanghe et al., 2010).”
Self-citationImaging of cerebrovascular pathology in animal models of Alzheimer's disease
Klohs, J., Rudin, M., Shimshek, D. R., & Beckmann, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00032 · Cited by 82
“…APP/Ld, APP/V717I, APP[V717I]) hAPP695 V717I mThy1 Lon 10–11 mo 12–15 mo ++ No Yes Moechars et al., 1999; Dewachter et al., 2000; van Dorpe et al., 2000; Tanghe et al., 2010; Perez-Cruz et al., 2011 BRI-Aβ42 BRI-Ab42 fusion MoPrP 3 mo 12 mo ++ n.a. n.a. McGowan et al., 2005 APPArcSwe…”
BackgroundRogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-61 · Cited by 75
Self-citation
Metadata
- Authors
- Tanghe, A., Termont, A., Merchiers, P., Schilling, S., Demuth, H.-U., Scrocchi, L., Van Leuven, F., Griffioen, G., & Van Dooren, T.
- Venue
- International Journal of Alzheimer's Disease
- Publisher
- Hindawi Limited
- Published
- 2010
- Volume
- 2010
- Pages
- 1-9
- ISSN
- 2090-0252 (ISSN-L)
- OpenAlex
- W2154482916
- Cited by
- 30
- References
- 14
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.